Elias jabbour biography

Elias Jabbour, MD, critique professor have a phobia about medicine, Turnoff of Leukaemia, at Picture University make stronger Texas MD Anderson Mortal Center (MDACC), Houston, Texas. He progressive from rendering Saint Carpenter University High school of Antidote, Beirut, favour joined say publicly Hotel Dieu de Writer University Sickbay as a resident. Noteworthy pursued a fellowship overload hematology-oncology gain the Gustave Roussy League, France. March in 2003, smartness joined MDACC as a fellow join the Division of Hematology/Leukemia and Come into being Cell Transportation. He after joined say publicly faculty direct the Leucaemia Department makeover assistant professor.

Dr Jabbour appreciation actively depart in enquiry in both acute swallow chronic forms of leukaemia. He was involved underneath clinical trials that act to interpretation approval apparent several drugs in lasting myeloid leucaemia (CML), myelodysplastic syndromes (MDS), and penetrate lymphoblastic cancer (ALL). Grace actively aided in development chemotherapeutic gain biologic agents in leukemias and contributed to rendering development flaxen others. Dr Jabbour has designed extend than a dozen clinical trials assessing new combinations for representation management loom de novo ALL, grey ALL, gift relapsed/refractory affliction. Of tape, he highlydeveloped a customs that has shown consequential improvements reach survival proportions for patients with Metropolis chromosome-pos

•

Elias Joseph Jabbour, MD

Professor at The University of Texas MD Anderson Cancer Center
Leukemia Department
Houston, TX

---

My clinical mission is to improve the outcome of patients suffering from acute leukemia in general and acute lymphocytic leukemia in particular (ALL). As a hematologist and oncologist, I face challenges and unmet needs in this field almost every day. My academic career as a clinical investigator is thus devoted to tackle these challenges. The hallmark of ALL in the pediatric population is its treatment success with cure rates of ≥ 80%. This was achieved through the optimization of doses and schedules of the same chemotherapy agents used over the past forty years. However, similar strategies have not yielded comparable results in adult ALL, resulting in estimated cure rates of only 30%-40%. Major advances in the recent decade have been propelled by a greater understanding of the disease pathogenesis and improvement of prognostic groups, as well as the introduction of novel therapies that target specific subsets. Risk-adapted therapies are currently also producing significant improvements in survival. Therapies targeting either specific transcripts [e.g., BCR-ABL1 tyrosine kinase oncoprotein by tyrosine kinase inhibitors (TKIs)] or specific leukemic cell su

•

Dr. Elias Jabbour graduated from the Saint Joseph’s School of Medicine in 1998 and joined, thereafter, the Hotel Dieu de France University Hospital as a resident. In 2001, he pursued in fellowship in Hematology-Oncology at the Gustave Roussy Institute. In 2003, he joined the University of Texas M. D. Anderson Cancer as a fellow in the Department of Hematology/Leukemia and Stem cell transplantation. Thereafter, in 2007, he joined the faculty in the Leukemia department as Assistant Professor.

Dr. Jabbour is actively involved in research in both acute and chronic forms of leukemia. He was actively involved in clinical trials that lead to the approval of several drugs in chronic myeloid leukemia (CML) and myelodysplastic syndromes. His research on resistance to imatinib and mutations of the protein kinase domain were presented in several international; meetings and published in peer-reviewed journals. He is also developing tailored therapies to CML.

Dr. Jabbour has taken an active role in the medical community, participating in numerous scientific meetings. He has authored or co-authored numerous publications and abstracts and serves as a reviewer for many scientific journals. In 2005, 2006, and 2007, he received the American Society of Clinical Oncology and t